

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification<sup>6</sup>:C07K 14/445, A61K 39/015, C12N 5/08,  
15/30

A2

(11) International Publication Number:

WO 95/26982

(43) International Publication Date:

12 October 1995 (12.10.95)

(21) International Application Number: PCT/GB95/00737

(22) International Filing Date: 31 March 1995 (31.03.95)

(30) Priority Data:

9406492.0

31 March 1994 (31.03.94)

GB

(71) Applicant (for all designated States except US): ISIS INNO-  
VATION LIMITED [GB/GB]; 2 South Parks Road, Oxford  
OX1 3UB (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HILL, Adrian, Vivian,  
Sinton [IE/GB]; 2 St Andrew's Road, Oxford OX3 9DL  
(GB). AIDOO, Michael [GH/GB]; Arthur Sanctuary House,  
John Radcliffe Hospital, Oxford OX3 9DU (GB). ALL-  
SOPP, Catherine, Elizabeth, Margaret [GB/GB]; 50 Benson  
Road, Oxford OX3 7EH (GB). LALVANI, Ajit [GB/GB];  
29 Wamborough Road, Oxford OX2 6JA (GB). PLEBAN-  
SKI, Magdalena [MX/GB]; 26 Benson Road, Oxford OX3  
7EH (GB). WHITTLE, Hilton, Carter [GB/GM]; Medical  
Research Council Laboratories, P.O. Box 273, Fajara, Near  
Banjul (GM).(74) Agent: PENNANT, Pyers; Stevens Hewlett & Perkins, 1  
Serjeants' Inn, Fleet Street, London EC4Y 1LL (GB).(81) Designated States: JP, US, European patent (AT, BE, CH, DE,  
DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

## Published

Without international search report and to be republished  
upon receipt of that report.

(54) Title: MALARIA PEPTIDES

## (57) Abstract

8-11-Mer peptides are identified, from four *Plasmodium falciparum* antigens, circumsporozoite protein, thrombospondin-related anonymous protein, spirozoite hepatocyte binding antigen and liver-stage antigen-1, as actual or potential cytotoxic T lymphocyte epitopes for human leucocyte antigen class I molecules HLA-A2, HLA-B8, HLA-B7 and HLA-B17. Vaccines for immunization against malaria contain these peptides or oligonucleotides coding for them. A method of inducing primary cytotoxic T lymphocyte responses to a chosen antigen or microorganism comprises incubating lymphocytes *ex vivo* with the chosen antigen or microorganism in the presence of keyhole limpet haemocyanin.